

**Generic Name:** N/A

**Therapeutic Class or Brand Name:** Calcitonin Gene-Related Peptide (CGRP) Inhibitors and Selective Serotonin (5-HT) 1F Receptor Agonists

**Applicable Drugs (if Therapeutic Class):**

Aimovig™ (erenumab-aooe), Ajoovy™ (fremanezumab-vfrm), Emgality™ (galcanezumab-gnlm), Nurtec® ODT (rimegepant), Qulipta™ (atogepant), Reyvow™ (lasmiditan), Ubrelvy™ (ubrogepant)

**Preferred:** Ajoovy™ (fremanezumab-vfrm), Emgality™ (galcanezumab-gnlm)

**Non-preferred:** Aimovig™ (erenumab-aooe), Nurtec® ODT (rimegepant), Qulipta™ (atogepant), Reyvow™ (lasmiditan), Ubrelvy™ (ubrogepant)

**Date of Origin:** 10/2/2018

**Date Last Reviewed / Revised:** 8/14/2022

**PRIOR AUTHORIZATION CRITERIA**

(May be considered medically necessary when criteria I through IV are met)

- I. Documentation of one of the following diagnosis A through C AND must meet all criteria listed under applicable diagnosis:
  - A. Prevention of migraine
    1. Diagnosis of episodic or chronic migraine.
    2. Documentation of  $\geq 4$  migraine days per month for at least 3 months.
    3. Documentation of functional impairment due to migraines (e.g., MIDAS  $\geq 11$ , HIT-6  $> 50$ , severe pain, missed days at school or work, impaired activities of daily living).
    4. Documented treatment failure with two or more guideline recommended migraine prophylaxis medications, at optimized dosing, for a duration of at least 8 weeks. The medications tried must be from at least two of the following drug categories, or the member must have contraindication to all drug categories:
      - a. Anticonvulsant: topiramate, divalproex sodium
      - b. Beta-blocker: propranolol, metoprolol, atenolol
      - c. Antidepressant: amitriptyline, nortriptyline, duloxetine, venlafaxine
      - d. ACE Inhibitor or angiotensin receptor blocker: lisinopril, candesartan
    5. The prescription is for Ajoovy™ or Emgality™, or there is documented treatment failure or contraindication to Ajoovy™ and Emgality™.
  - B. Treatment of acute migraine
    1. Documented treatment failure or contraindication to two generic triptans at maximally tolerated doses with repeated use. The two triptans are required to differ in chemical entity and dosage form (oral, nasal, injection).
    2. If prescription is for Nurtec® ODT there must also be documented treatment failure or contraindication to Reyvow™ and Ubrelvy™.
  - C. Treatment of episodic cluster headaches

1. Documentation of at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months.
  2. Documented treatment failure with one or contraindication to all of the following: verapamil, lithium, and topiramate.
  3. Prescription is for Emgality™.
- II. Minimum age requirement: 18 years old.
- III. Request is for a medication with the appropriate FDA labeling, or its use is supported by current clinical practice guidelines. Refer to Table 1 for FDA approved indications.
- IV. Refer to plan document for the list of preferred products. If requested agent is not listed as a preferred product, must have a documented failure, intolerance, or contraindication to a preferred product(s).

## EXCLUSION CRITERIA

- Concurrent use of any of the following:
  - More than one CGRP Inhibitor within the same subclass (e.g., monoclonal antibody, gepant).
  - Reyvow™ with a GCRP inhibitor (e.g., Nurtec® ODT or Ubrelvy™) for the treatment of acute migraine.
- Patient suffers from rebound headaches due to medication overuse (medication overuse headache or MOH) or MOH has not been ruled out.

## OTHER CRITERIA

- N/A

## QUANTITY / DAYS SUPPLY RESTRICTIONS

- Ajovy™: One 225 mg prefilled syringe per 30 days or three 225 mg prefilled syringes (total 675 mg) per 90 days.
- Aimovig™: One 70 mg autoinjector or syringe or one 140 mg autoinjector or syringe per 30 days.
- Emgality™
  - Migraine prophylaxis: two 120 mg auto-injector pens or syringes for the first 30 days, then one 120 mg auto-injector pen or syringe per 30 days thereafter.
  - Episodic cluster headache: three 100 mg syringes per 30 days.
- Nurtec® ODT
  - Episodic migraine prophylaxis: 16 tablets per 30 days.

- Acute migraine treatment: 8 tablets per 30 days.
- Qulipta™
  - Episodic migraine prophylaxis: 30 tablets per 30 days.
- Reyvow™: 8 tablets per 30 days
- Ubrelvy™: 10 tablets per 30 days.

## APPROVAL LENGTH

- **Authorization:** 6 months.
- **Re-Authorization:** 1 year, with an updated letter of medical necessity or progress notes showing sustained clinical benefits from the drug treatment, including at least a 50% improvement in functional impairment and headache severity from baseline (as measured by a reduction in the need for acute abortive therapies or care, missed days at work or school, and increase in ability to perform activities of daily living compared to baseline).

## APPENDIX

Table 1

FDA-Approved Indications for Medications Used for Migraine Treatment and Prophylaxis

Medication	Acute Migraine Treatment	Episodic Migraine Prophylaxis	Chronic Migraine Prophylaxis	Cluster Headache Treatment
Ajovy™		✓	✓	
Aimovig™		✓	✓	
Emgality™		✓	✓	✓
Qulipta™		✓		
Nurtec® ODT	✓	✓		
Reyvow™	✓			
Ubrelvy™	✓			

## REFERENCES

1. Ailani, Jessica et al. "The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice." *Headache* vol. 61,7 (2021): 1021-1039. doi:10.1111/head.14153. Accessed August 14, 2022
2. Aimovig (erenumab-aooe) [prescribing information]. Thousand Oaks, CA: Amgen Inc; November 2021 [https://www.pi.amgen.com/~media/amgen/repositorysites/pi-amgen.com/aimovig/aimovig\\_pi\\_hcp\\_english.ashx](https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen.com/aimovig/aimovig_pi_hcp_english.ashx). Accessed August 14, 2022

3. Ajovy (fremanezumab-vfrm) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; September 2021 <https://www.ajovyhcp.com/globalassets/ajovy/ajovy-pi.pdf>. Accessed August 14, 2022
4. Emgality (galcanezumab-gnlm) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; March 2021 <https://uspl.lilly.com/emgality/emgality.html?s=pi>. Accessed August 14, 2022
5. Nurtec (rimegepant) [prescribing information]. New Haven, CT: Biohaven Pharmaceuticals Inc; April 2022 <https://biohaven-nurtec-consumer-assets.s3.amazonaws.com/nurtec-prescribing-information.pdf>. Accessed August 14, 2022
6. Qulipta (atogepant) [prescribing information]. Dublin, Ireland: Forest Laboratories Ireland Ltd; October 2021 [https://www.rxabbvie.com/pdf/QULIPTA\\_pi.pdf](https://www.rxabbvie.com/pdf/QULIPTA_pi.pdf). Accessed August 14, 2022
7. Reyvow (Lasmiditan) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; December 2021 <http://uspl.lilly.com/reyvow/reyvow.html?s=pi>. Accessed August 14, 2022
8. Robbins, Matthew S et al. "Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines." *Headache* vol. 56,7 (2016): 1093-106. doi:10.1111/head.12866. Accessed August 14, 2022
9. Silberstein, S D et al. "Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society." *Neurology* vol. 78,17 (2012): 1337-45. doi:10.1212/WNL.0b013e3182535d20. August 14, 2022
10. Ubrelvy (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA Inc; March 2021 [https://media.allergan.com/products/Ubrelvy\\_pi.pdf](https://media.allergan.com/products/Ubrelvy_pi.pdf). Accessed August 14, 2022
11. Wei, Diana Y et al. "Managing cluster headache." *Practical neurology* vol. 19,6 (2019): 521-528. doi:10.1136/practneurol-2018-002124. Accessed August 14, 2022

**DISCLAIMER:** Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.